Taurine 8 pp 59-66 | Cite as

The Effects of Bisphosphonates on Taurine Transport in Retinal Capillary Endothelial Cells Under High Glucose Conditions

  • Na-Young Lee
  • Young-Sook KangEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 776)


Diabetic retinopathy (DR) is a major cause of blindness in diabetic patients. Elevated glucose and vascular endothelial growth factor (VEGF) in retina can trigger many of the retinal vascular changes caused by diabetes and DR. Recently, bisphosphonates, antiosteoporosis drugs, have been reported to have anti-angiogenic effect by decreasing VEGF. Taurine has several biological processes such as osmoregulation and antioxidation in retina. Therefore, the purpose of this study is to clarify the regulation of taurine transport activity by high glucose concentration and the effect of inhibitors for VEGF function, bisphosphonates, on taurine transport under high glucose condition using TR-iBRB cell lines as an in vitro model of inner blood-retinal barrier (iBRB). As a result, by exposing TR-iBRB cells to high glucose for 48 h, [3H]taurine uptake was decreased continuously. [3H]Taurine uptake was increased significantly by pretreatment of alendronate and pamidronate compared with the values for high glucose. Increased [3H]taurine uptake by pretreatment of alendronate and pamidronate was significantly reduced by mevalonate pathway intermediates, geranylgeraniol (GGOH). In conclusion, taurine transport through the iBRB under high glucose condition can be regulated by bisphosphonates via mevalonate pathway. Therefore, we suggest that bisphosphonates could have the beneficial effects on DR by regulation of taurine contents in retina.


Vascular Endothelial Growth Factor Diabetic Retinopathy Osteogenesis Imperfecta Retinal Pigment Epithelial Cell Mevalonate Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Inner blood-retinal barrier


Diabetic retinopathy


Vascular endothelial growth factor




Taurine transporter



This work was supported by the Research Grant of Sookmyung Women’s University.


  1. Andela VB, Pirri M, Schwarz EM, Puzas EJ, O’Keefe RJ, Rosenblatt JD, Rosier RN (2003) The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res 415(Suppl):S59–S66PubMedCrossRefGoogle Scholar
  2. Ando D, Kubo Y, Akanuma S, Yoneyama D, Tachikawa M, Hosoya K (2012) Function and regulation of taurine transport in Müller cells under osmotic stress. Neurochem Int 60:597–604PubMedCrossRefGoogle Scholar
  3. El-Sherbeny A, Naggar H, Miyauchi S, Ola MS, Maddox DM, Martin PM, Ganapathy V, Smith SB (2004) Osmoregulation of taurine transporter function and expression in retinal pigment epithelial, ganglion, and Müller cells. Invest Ophthalmol Vis Sci 45:694–701PubMedCrossRefGoogle Scholar
  4. Frank RN (1984) On the pathogenesis of diabetic retinopathy. Ophthalmology 91:626–634PubMedGoogle Scholar
  5. Frank RN (2004) Diabetic retinopathy. N Eng J Med 350:48–58CrossRefGoogle Scholar
  6. Geggel HS, Ament ME, Heckenlively JR, Martin DA, Kopple JD (1985) Nutritional requirement for taurine in patients receiving long-term parenteral nutrition. N Engl J Med 312:142–146PubMedCrossRefGoogle Scholar
  7. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL, Stacker SA, Cooper ME (1998) Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78:1017–1027PubMedGoogle Scholar
  8. Heller-Stilb B, van Roeyen C, Rascher K, Hartwig HG, Huth A, Seeliger MW, Warskulat U, Häussinger D (2002) Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J 16:231–233PubMedGoogle Scholar
  9. Hosoya K, Tomi M, Ohtsuki S, Takanaga H, Ueda M, Yanai N, Obinata M, Terasaki T (2001) Conditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat. Exp Eye Res 72:163–172PubMedCrossRefGoogle Scholar
  10. Jacobsen JG, Smith LH (1968) Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev 48:424–511PubMedGoogle Scholar
  11. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ (2005) JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 20:1265–1274PubMedCrossRefGoogle Scholar
  12. Mathews MK, Merges C, McLeod DS, Lutty GA (1997) Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2729–2741PubMedGoogle Scholar
  13. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP (2000) Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156:1733–1739PubMedCrossRefGoogle Scholar
  14. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J (1997) Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 273:H2224–H2231PubMedGoogle Scholar
  15. Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248:915–930PubMedCrossRefGoogle Scholar
  16. Pasantes-Morales H, Klethi J, Ledig M, Mandel P (1972) Free amino acids of chicken and rat retina. Brain Res 41:494–497PubMedCrossRefGoogle Scholar
  17. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMedGoogle Scholar
  18. Schrufer TL, Antonetti DA, Sonenberg N, Kimball SR, Gardner TW, Jefferson LS (2010) Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Muller cells in culture. Diabetes 59:2107–2116PubMedCrossRefGoogle Scholar
  19. Stevens MJ, Hosaka Y, Masterson JA, Jones SM, Thomas TP, Larkin DD (1999) Down regulation of the human taurine transporter by glucose in cultured retinal pigment epithelial cells. Am J Physiol 277:760–771Google Scholar
  20. Terasaki T, Hosoya K (2001) Conditionally immortalized cell lines as a new in vitro model for the study of barrier functions. Biol Pharm Bull 24:111–118PubMedCrossRefGoogle Scholar
  21. Tomi M, Terayama T, Isobe T, Egami F, Morito A, Kurachi M, Ohtsuki S, Kang YS, Terasaki T, Hosoya K (2007) Function and regulation of taurine transport at the inner blood–retinal barrier. Microvasc Res 73:100–106PubMedCrossRefGoogle Scholar
  22. Törnquist P, Alm A (1986) Carrier-mediated transport of amino acids through the blood–retinal and the blood–brain barriers. Graefe’s Arch Clin Exp Ophthalmol 224:21–25CrossRefGoogle Scholar
  23. Yokota T, Utsunomiya K, Taniguchi K, Gojo A, Kurata H, Tajima N (2007) Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol 51:424–430PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.College of Pharmacy and Research Center for Cell Fate ControlSookmyung Women’s UniversitySeoulSouth Korea

Personalised recommendations